# Short and Optimal Duration of Dual Antiplatelet Therapy Study

> **NCT01659034** · PHASE4 · COMPLETED · sponsor: **Takeshi Morimoto** · enrollment: 1525 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Thienopyridine for 3 months

## Key facts

- **NCT ID:** NCT01659034
- **Lead sponsor:** Takeshi Morimoto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 1525 (ACTUAL)
- **Last updated:** 2015-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01659034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01659034, "Short and Optimal Duration of Dual Antiplatelet Therapy Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01659034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*